We advised Adagene on the offering

Davis Polk advised Adagene Inc. in connection with its SEC-registered at-the-market offering of American depositary shares having an aggregate offering price of up to approximately $100 million. Adagene’s ADSs are listed on Nasdaq under the symbol “ADAG.”

Adagene is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.

The Davis Polk capital markets team included partner Xuelin (Steve) Wang and associate Xin (Sheen) Xu. The tax team included counsel Alon Gurfinkel and associates Charles Collier and Ben Silver. Partner Gregory S. Rowland, counsel Sarah E. Kim and associate Caroline R. Zhang provided Investment Company Act advice. 

Members of the Davis Polk team are based in the Hong Kong, New York and London offices.

Copy link to share post